Eosinophilic Esophagitis Treatment Guidelines
First-Line Treatment
- The American Gastroenterological Association (AGA) suggests using proton pump inhibitors (PPIs) over no treatment for eosinophilic esophagitis (EoE) patients, with a conditional recommendation 1
- PPI therapy should be started with twice-daily dosing for 8-12 weeks before assessing histological response, as it is effective in inducing both histological and clinical remission in EoE patients 2
- For patients who achieve histological response, PPI therapy is effective for maintaining remission 2
Second-Line Treatment
- Topical corticosteroids are indicated when PPI therapy fails to achieve adequate response, with high-grade evidence supporting their effectiveness for inducing histological and clinical remission 2
- Topical steroids are preferred over oral corticosteroids due to a better safety profile 1
- Maintenance treatment with topical steroids should be recommended following clinical review, as relapse rates are high after withdrawal 2
- Topical steroids likely reduce the development of strictures in EoE patients 2
Dietary Approaches
- The American Gastroenterological Association (AGA) suggests considering elimination diets after inadequate response to medication or as an alternative first-line approach for EoE patients 1
- An elemental diet has the highest efficacy but lowest compliance, and should be reserved for patients refractory to other treatments 2, 1
- An empiric 6-food elimination diet removes common allergenic foods and has moderate evidence of effectiveness 1
Management of Complications
- Endoscopic dilatation is effective and safe for improving symptoms in patients with strictures, and can be performed using either balloon or bougie dilators 2
- Best outcomes are achieved when endoscopic dilatation is combined with effective anti-inflammatory therapy using topical steroids 2
Treatment for Refractory Cases
- Novel biologics (dupilumab, cendakimab, benralizumab) show promise but are currently recommended only for patients with coexisting allergic diseases 2, 3
- Anti-IL-5 pathway agents like mepolizumab have shown reduction in eosinophil count but limited symptom improvement 3
- Anti-IL-13 monoclonal antibody cendakimab has demonstrated significant reduction in eosinophil count and dysphagia scores in phase 2 trials 3
Monitoring and Follow-up
- If symptoms recur while on treatment, repeat endoscopy for assessment and obtain further histology 2
- Endoscopists should be aware that they may underestimate the frequency of strictures and narrow lumen esophagus in EoE patients 2
Multidisciplinary Management
- Patients with EoE refractory to treatment and/or with significant concomitant atopic disease should be jointly managed by a gastroenterologist and specialist allergist 2, 4
- Joint allergy clinics with an allergist and dietician are suitable for children with EoE who have other atopic diseases 4
Management of Eosinophilic Esophagitis (EoE)
Maintenance Therapy
- The American Gastroenterological Association recommends continued PPI therapy, possibly at reduced dose, as a maintenance option for EoE patients who achieve initial response 5
- Maintenance therapy with topical corticosteroids, possibly at lower maintenance dose, is also recommended for patients who respond to this approach 5
- Continued dietary elimination is an option for maintenance therapy in patients who responded to this approach, with limited evidence existing for optimal maintenance dosing, but continued therapy is important to prevent disease progression to fibrostenotic disease 5, 6
Management of Complications
- Endoscopic dilation has a pooled perforation rate of approximately 0.4%, with most complications occurring before 2009, and is effective and safe for improving symptoms in patients with strictures 5